Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Tim Boreham highlights the success of Paradigm Biopharmaceuticals' joint pain drug ahead of a capital raising. by Tim Boreham ASX code: ((PAR)) Share price: 41.5c Shares on issue: 281,756,625 (pre capital raise) Market cap: $116.9 m Executi...

Despite improving sentiment in the life sciences sector, investors are savagely discounting pre-clinical drug developers with a long path to approval. That’s fair enough – investors are risk averse generally – but many worthy drug developer...

The ASX200 started November with a gain of more than three-quarters of a per cent (.85 of a per cent). Most sectors were in the green. Real estate and health care both had strong runs. In the green BHP Group (ASX:BHP) was up 1.5 pe...

The S&P/ASX 200 Index (ASX: XJO) is having a strong session on Wednesday. In afternoon trade, the benchmark index is up 0.65% to 6,825.3 points. Four ASX shares that have failed to follow the market's lead today are listed below. Here...

IDT provides strong quarterly update Paradigm tumbles 30pc after emerging from trading halt   IDT’s growth driven by all business segments Victoria-based pharmaceutical manufacturing company, IDT Australia (ASX:IDT), provided an update on...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt and crashed deep into the red. In morning trade, the ASX All Ords share is down 34% to a 52-week low of 40.5 cents. Why is this ASX All Ords shar...

Benchmark ASX closes below 6,800 points  All Sectors in red, but for IT Small caps led, in a very big way, by TG6    The benchmark has ended sharply lower after weak overseas leads, strong retail data and an all-round international-flavou...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Research reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=BF0A410A-F5BF-4E00-5CA139523262B26D –Bell Financial Gro...

The Australian sharemarket increased in value on Wednesday, as China's gross domestic product (GDP) for July-September grew by 4.9% compared to the previous year.  At the closing bell, the S&P/ASX 200 was 0.3 per cent higher at 7,077.60...

There have been some big movers in the healthcare sector on Wednesday. Here's why these ASX healthcare shares are up over 10% today: Mayne Pharma Group Ltd (ASX: MYX) The Mayne Pharma share price is up over 13% to $3.12. Investors have be...

  Don't miss Friday's webinar discussing imaging tech, laser tech and agricultural REITs. Click here to register. Whitehaven Coal (ASX:WHC) has been placed in a trading halt following an announcement by BHP that Whitehaven Coal is the prefe...

18 Oct 2023 - A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Biopharmaceuticals (ASX:PAR), Noxopharm (ASX:NOX) and Liontown Resources (ASX:LTR)…

Paradigm Biopharma (ASX:PAR) reports it has proven it can reverse the degradation of cartilage in patients with osteoarthritis The company is using injectable pentosan polysulfate sodium (iPPS) delivered twice weekly over six weeks...

ASX futures were down 0.43 per cent at 8.30 am AEDT as US indexes landed in the red on Friday. The S&P 500 ended down by half a per cent and the NASDAQ down 1.23 per cent. The Dow Jones ended up 0.12 per cent. In the US, energy w...

  Paul Rennie – Founder and Managing Director – Paradigm Biopharmaceuticals Limited (ASX:PAR) is a global biopharmaceutical company. Its current focus is a drug for the treatment of osteoarthritis.

The S&P/ASX 200 surged back above 7000 on Tuesday, driven by a shift in rhetoric from US Federal Reserve members towards a more dovish stance and signs of easing inflation. The benchmark closed 1% higher at 7040, marking its best one-da...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

  Paradigm Pharmaceuticals phase II study for treatment of knee osteoarthritis reports successful outcome at day 356 Clinical outcomes improvement observed for iPPS twice weekly compared to placebo control Company now intends to proceed wi...

Paradigm Biopharma set to submit application to TGA EMVision uses artificial intelligence simulation   Paradigm to submit TGA application after successful trial Paradigm Biopharmaceuticals (ASX:PAR) jumped 13% this morning after reporting...

Paradigm Biopharma (ASX:PAR) reports injectable pentosan polysulfate has led to a decrease in self-reported pain in osteoarthritis (OA) patients The company says results show iPPS is likely a superior drug compared to other major treatm...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been catching the eye on Tuesday. At one stage today, the ASX healthcare share was up over 18% to 73.5 cents. The Paradigm share price has pulled back a touch since then but re...

Oil prices held steady following a significant surge as Israel indicated that its retaliation against Hamas attacks had just begun, raising concerns of increased instability in the region. The conflict's potential impact on global oil suppl...

Late-stage drug development company Paradigm Biopharmaceuticals (ASX: PAR) has announced positive study data from a Phase 2 clinical trial of injectable pentosan polysulfate sodium (iPPS) for the treatment of acute pain associated with knee...

10 Oct 2023 - A snapshot of the stocks on the move, featuring Atlantic Lithium (ASX:A11), Raiden Resources (ASX:RDN) and Paradigm Biopharmaceuticals (ASX:PAR).

  Atlantic Lithium (AIM:ALL, ASX:A11, OTCQX:ALLIF) receives authorisation to commence the diversion of the transmission lines crossing the Mankessim Licence, moving a step closer to shovel readiness at the Ewoyaa Lithium Project. Shares are...

Stockhead’s Top 10 at shortly-before-11-ish, produced with gritted teeth as, once again, the local council has decided that it needs to pay some drongo to stand outside my house all day waving a leaf blower around while screaming into his c...

Research reports on ASX-listed companies, to download in full. **** –Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=740BB0E6-015D-39AE-7477F8A8DFBEC04C –Millennium Service...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. The benchmark index is currently down 0.15% to 7,235.2 points. Four ASX shares that are falling more than most today are listed below. Hereâ€...

Futures suggest Australian shares will open relatively unchanged in the face of the RBA interest rate decision this afternoon. Here are some ASX-listed companies with news out today: In healthcare, Paradigm Biopharmaceuticals (PAR) h...

Research reports on ASX-listed companies, to download in full. **** –AFT Pharmaceuticals ((AFP)) – Edison Research: https://www.fnarena.com/index.php/download-article/?n=5CCC26AF-A670-63C8-370E356F819BE3C4 –Barrow Handley Global Share Fund...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

The ASX is set to open lower on Thursday US debt ceiling deal passed to Senate after the House voted 241-187 Crude prices have fallen by another -2.7%   Aussie shares are set to open lower on Thursday after the shock inflation report yest...

Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy. MELBOURNE, Australia, May 25, 2023 /PRNewswire/ — With the launch of a new website dedicated to their global clinical trials...

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...

The ASX closed in the green, despite teetering around midday after RBA Governor Philip Lowe dampened confidence that interest rates may peak. Mr Lowe warned Australians that the pause may be just temporary, and further interest rate hike...

Paradigm Biopharmaceuticals (PAR) claims a trial of its injectable pentosan polysulfate sodium (iPPS) drug shows the treatment may slow disease progression in knee osteoarthritis (OA) The company has reported data from day 168 of its pha...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and slipped into the red. At the time of writing, the benchmark index is down slightly to 7,221.3 points. Four ASX shares that are falling more tha...

Paradigm Biopharma demonstrates efficacy of knee osteoarthritis drug Race Oncology released a third-party report showing the potential for Zantrene Emyria and Aspen Australia have signed an exclusive binding deal   Paradigm Biopharmaceuti...

ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week (and year) in a positive fashion. In afternoon trade, the benchmark index is up 0.55% to 7,057.8 points. Four ASX shares that are climbing more than most today are listed b...

Paradigm Biopharmaceuticals (PAR) receives a notice of allowance from the US Patent and Trademark Office (USPTO) The notification demonstrates PAR’s patent application has been examined and satisfies the requirements for patentability The p...

The ASX is poised to open higher on Wednesday after a rally in New York Oil prices higher as Saudi said OPEC+ wasn’t considering output increase Crypto broker Genesis near bankcruptcy The ASX is set to open higher on Wednesday after a bro...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.6% to 7,184.3 points. Four ASX shares that have failed to follow the market higher today a...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day. In afternoon trade, the biotechnology company’s shares are down 12% to $1.48. This makes the Paradigm share price one of the worst performers on the Al...

Paradigm Pharmaceuticals’ (PAR) CEO, Marco Polizzi, has stepped down from his role after just five months with the companyMr Polizzi will exit the role on February 20, 2023, and Paradigm did not say why he was stepping downParadigm has appo...

Bod Australia returns positive results from Phase 1 trial Paradigm and Impedimed make executive changes Creso Pharma no longer the subject of ASIC investigation Cannabis stock Bod Australia (ASX:BOD) announced positive results from its Ph...